Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2006-11-14
2006-11-14
Brumback, Brenda (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C424S161100, C514S012200
Reexamination Certificate
active
07135170
ABSTRACT:
IL-28A, IL-28B, IL-29, and certain mutants thereof have been shown to have antiviral activity on a spectrum of viral species. Of particular interest is the antiviral activity demonstrated on viruses that infect liver, such as hepatitis B virus and hepatitis C virus. In addition, IL-28A, IL-28B, IL-29, and mutants thereof do not exhibit some of the antiproliferative activity on hematopoietic cells that is observed with interferon treatment. Without the immunosuppressive effects accompanying interferon treatment, IL-28A, IL-28B, and IL-29 will be useful in treating immunocompromised patients for viral infections.
REFERENCES:
patent: 5206344 (1993-04-01), Katre et al.
patent: 2002/0039763 (2002-04-01), Sheppard et al.
patent: 2003/0104416 (2003-06-01), Sheppard et al.
patent: 2004/0029228 (2004-02-01), Presnell et al.
patent: 2004/0138122 (2004-07-01), Klucher et al.
patent: 0 032 134 (1981-07-01), None
patent: 02/20569 (2002-03-01), None
patent: 02/086087 (2002-10-01), None
patent: 02/092762 (2002-11-01), None
patent: 03/066002 (2003-08-01), None
patent: 03/089603 (2003-10-01), None
patent: 04/037995 (2004-05-01), None
Kotenko et al., “IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex,”Nature Immunology 4(1):69-77, 2003.
Sheppard et al., “IL-28, Il-29 and their class II cytokine receptor IL-28R,”Nature Immunology 4(1):63-68, 2003.
Langer et al., “The Class II cytokine receptor (CRF2) family: overview and patterns of receptor-ligand interactions,”Cytokine and Growth Factor Reviews 15:33-48, 2004.
Donnelly et al., “The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain,”J. Leukocyte Biol. 76:314-321, 2004.
Dumoutier et al., “Role of the Interleukin (IL)-28 Receptor Tyrosine Residues for Antiviral and Antiproliferative Activity of IL-29/Interferon-λ1,”J. Biochem. 279(31):32269-32274, 2004.
University Calif. Santa Cruz Genome Browser—Chromosome 19, Apr. 20, 2001.
University Calif. Santa Cruz Genome Browser Database—Aug. 6, 2001, Accession No. C19001210.
University Calif. Santa Cruz Genome Browser Database—Aug. 6, 2001, Accession No. C19001212.
University Calif. Santa Cruz Genome Browser Database—Aug. 6, 2001, Accession No. C19001213.
University Calif. Santa Cruz Genome Browser Database—Dec. 22, 2001, Accession No. C19001260.
University Calif. Santa Cruz Genome Browser Database—Dec. 22, 2001, Accession No. C19001256.
University Calif. Santa Cruz Genome Browser Database—Dec. 22, 2001, Accession No. C19001257.
Ensembl Contig. View Sanger Institute—Apr. 19, 2001, Accession No. AC011445.
Ensembl Contig. View Sanger Institute—Apr. 18, 2000, Accession No. AC018477.
Adams et al., “3,400 expressed sequence tags identify diversity of transcripts from human brain,”Nat. Genet. 4:256-267, 1993.
GenBank Submission XP-002202436, Oct. 12, 2000.
GenBank Submission XP-002202437, Dec. 12, 1999.
Kindsvogel et al., “Novel Interferon-Like Cytokines not Recognized by the Type I Interferon Receptor,”J. Interferon Cytokine Res. 22(1):S-48, 2002.
Adams et al., Accession No. T07139, 1993.
DOE Joint Genome Institute Stanford Human Genome Center, Accession No. AC011445, 1999.
Muzney et al., Accession No. AC007458, 1999.
University of California Santa Cruz database using Softberry, Inc. gene prediction software, Accession No. C19001084, 2001.
Scott et al., “The Pendred syndrome gene encodes a chloride-iodide transport protein,”Nature Genetics,21:440-443, 1999.
Korba et al., “A cell culture assay for compounds which inhibit hepatitis B virus replication,”Antiviral Research 15:217-228, 1991.
Brack et al., “Molecular analysis of the human interferon-α gene family,”Gene 15:379-394, 1981.
Francis et al., “PEGylation of cytokines and other therapeutic proteins and peptides: the importance of biological optimization of coupling techniques,”International Journal of Hematology,68(1):1-18, 1998.
Rajarathnam et al., “Disulfide Bridges in Interleukin-8 Probed Using Non-Natural Disulfide Analogues: dissociation of Roles in Structure from Function,”Biochemistry 38:7653-7658, 1999.
Luxon et al., “Pegylated Interferons for the Treatment of Chronic Hepatitis C Infection,”Clinical Therapeutics 24(9):13631383, 2002.
Kozlowski et al., “Improvements in protein OEGylation: pegylated interferons for treatment of hepatitis C,”Journal of Controlled Release 72:217-224, 2001.
Goodson et al., “Site-Directed Pegylation of Recombinant Interleukin-2 at its Glycosylation Site,”Bio/Technology 8(4):343-346, 1990.
Pettit et al., “Structure-Function Studies of Interleukin 15 using Site-specific Mutagenesis, Polyethylene Glycol Conjugation, and Homology Modeling,”J. Biochem 272(4):2312-2318, 1997.
Vilcek, “Novel interferons,” Nature Immunology 4(1):8-9, 2003.
U.S. Appl. No. 60/700,905, filed Jul. 20, 2005, Sheppard et al.
Henderson Katherine E.
Kindsvogel Wayne R.
Klucher Kevin M.
Sivakumar Pallavur V.
Brumback Brenda
Hamud Fozia
Walsh Brian J.
ZymoGenetics Inc.
LandOfFree
Methods for treating viral infection using IL-28 and IL-29 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating viral infection using IL-28 and IL-29, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating viral infection using IL-28 and IL-29 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3623798